Literature DB >> 7947086

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.

R Colomer1, R Lupu, S S Bacus, E P Gelmann.   

Abstract

Amplification and overexpression of the erbB-2 oncogene is an unfavourable prognostic marker in human breast cancer and occurs in approximately 25% of breast carcinomas. We used erbB-2 antisense oligonucleotides to inhibit the proliferation of human breast cancer cell lines. erbB-2 antisense oligonucleotides (20 microM) inhibited the growth and DNA synthesis of breast cancer cell lines with an amplified erbB-2 gene by up to 60%. Control complementary sense oligonucleotides did not inhibit cellular proliferation at the same concentration but showed inhibitory effects at higher concentrations. There was no specific effect of erbB-2 antisense oligonucleotides on breast cancer cell lines that had no amplification of erbB-2. erbB-2 antisense oligonucleotides reduced erbB-2 protein levels, measured by immunohistochemistry, in a dose-dependent manner. erbB-2 sense oligonucleotides did not decrease the levels of erbB-2 protein. These data indicate that erbB-2 antisense oligonucleotides induce a specific inhibition of erbB-2 protein expression and that erbB-2 gene overexpression is important for the proliferation of the breast cancer cells that have been selected for erbB-2 amplification.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947086      PMCID: PMC2033560          DOI: 10.1038/bjc.1994.405

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

1.  An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation.

Authors:  J T Holt; R L Redner; A W Nienhuis
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

2.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

Authors:  R M Hudziak; J Schlessinger; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Increased erbB-2 gene copies and expression in multiple stages of breast cancer.

Authors:  J D Iglehart; M H Kraus; B C Langton; G Huper; B J Kerns; J R Marks
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

4.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

Authors:  J A Drebin; V C Link; D F Stern; R A Weinberg; M I Greene
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

6.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

7.  Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.

Authors:  E L Wickstrom; T A Bacon; A Gonzalez; D L Freeman; G H Lyman; E Wickstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

8.  Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.

Authors:  J A Drebin; V C Link; R A Weinberg; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

Authors:  L Coussens; T L Yang-Feng; Y C Liao; E Chen; A Gray; J McGrath; P H Seeburg; T A Libermann; J Schlessinger; U Francke
Journal:  Science       Date:  1985-12-06       Impact factor: 47.728

10.  Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

Authors:  M H Kraus; N C Popescu; S C Amsbaugh; C R King
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  19 in total

Review 1.  Perspectives of HER2-targeting in gastric and esophageal cancer.

Authors:  James N Gerson; Sam Skariah; Crystal S Denlinger; Igor Astsaturov
Journal:  Expert Opin Investig Drugs       Date:  2017-05       Impact factor: 6.206

2.  Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells.

Authors:  Timo Faltus; Juping Yuan; Brigitte Zimmer; Andrea Krämer; Sibylle Loibl; Manfred Kaufmann; Klaus Strebhardt
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

3.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.

Authors:  J Q Cheng; B Ruggeri; W M Klein; G Sonoda; D A Altomare; D K Watson; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

4.  Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Authors:  Debyani Chakravarty; Elmer Santos; Mabel Ryder; Jeffrey A Knauf; Xiao-Hui Liao; Brian L West; Gideon Bollag; Richard Kolesnick; Tin Htwe Thin; Neal Rosen; Pat Zanzonico; Steven M Larson; Samuel Refetoff; Ronald Ghossein; James A Fagin
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

5.  Neuregulins signaling via a glial erbB-2-erbB-4 receptor complex contribute to the neuroendocrine control of mammalian sexual development.

Authors:  Y J Ma; D F Hill; K E Creswick; M E Costa; A Cornea; M N Lioubin; G D Plowman; S R Ojeda
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

6.  Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.

Authors:  Alex Kentsis; Ivan Topisirovic; Biljana Culjkovic; Ling Shao; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-15       Impact factor: 11.205

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

8.  An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro.

Authors:  N Sugawa; S Ueda; Y Nakagawa; H Nishino; K Nosaka; A Iwashima; M Kurimoto
Journal:  J Neurooncol       Date:  1998-09       Impact factor: 4.130

Review 9.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

10.  Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

Authors:  R R Beerli; D Graus-Porta; K Woods-Cook; X Chen; Y Yarden; N E Hynes
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.